Emerging treatments
High-dose rifampin regimens
Higher doses of rifampin have been associated with improved clinical response. In one randomized controlled trial, patients treated with high-dose rifampin plus standard-dose doxycycline had significantly higher clinical response rates compared with patients treated with standard-dose rifampin and standard-dose doxycycline, (95% versus 82%), without further adverse effects. These findings need to be confirmed in future studies before higher doses of rifampin are recommended.[141]
Hydroxychloroquine-based regimens
Hydroxychloroquine, an antiprotozoal agent often used for the treatment of malaria, has been shown to improve the efficacy of the doxycycline plus streptomycin regimen in clinical trials, as well as reduce the risk of relapse. However, further research is required.[142][143]
Use of this content is subject to our disclaimer